Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $192.1

Benzinga · 1d ago
Wedbush analyst Robert Driscoll maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and raises the price target from $181 to $192.1.